Navigation Links
InfraReDx Awarded 2010 Tax Incentive From Massachusetts Life Sciences Center
Date:12/23/2010

BURLINGTON, Mass., Dec. 23, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has been selected to receive an award of nearly $862,000 as part of the Massachusetts Life Sciences Center (MLSC) Tax Incentive Program. In conjunction with the award, InfraReDx has committed to create 32 new jobs during 2011.  

The Life Sciences Tax Incentive Program was established in 2008 as part of the state's 10-year, $1 billion Life Sciences Initiative. The program authorizes up to $25 million in tax incentives each year to expand life sciences-related employment opportunities, promote health-related innovations, and stimulate research and development, manufacturing and commercialization in the life sciences. The primary goal of the program is to incentivize life sciences companies to create new long-term jobs in Massachusetts.

"We are very pleased to be a recipient of these incentive funds for the second year in a row," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "There is an excellent fit between the goals of the Massachusetts Life Sciences Center and the stage of development that InfraReDx has reached. The MLSC seeks to expand life sciences-related jobs in Massachusetts; InfraReDx is a medical device company that has thrived because of the life sciences expertise concentrated in Massachusetts. The company has developed the LipiScan™ IVUS combination coronary catheter that uses both light and sound (near-infrared spectroscopy and intra-coronary ultrasound) to identify the fatty plaques that cause complications during stenting and are associated with heart attacks occurring in the community. We continue to hire life science workers to build additional systems and catheters to satisfy the rapidly growing demand for the product coming from hospitals throughout the world."

This year, the MLSC has named a total of $23.9 million in tax incentives for 30 life sciences companies.  The companies receiving the awards – typically late-stage life science companies transitioning from research and development to commercialization and manufacturing – have committed to creating nearly 1,000 new jobs in the Commonwealth over the coming year.

About InfraReDx, Inc.InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx's LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit www.infraredx.com.  Contacts:Susan Heins (media)Pure Communications, Inc. 864-286-9597sjheins@purecommunicationsinc.com Grant FrazierVice President of MarketingInfraReDx, Inc.781-345-9632gfrazier@infraredx.com
'/>"/>

SOURCE InfraReDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System
2. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
3. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
4. InfraReDx Completes $21 Million Equity Financing
5. InfraReDxs New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010
6. InfraReDxs LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
7. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
8. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
9. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
10. Pepex™ Awarded Qualifying Therapeutic Discovery Project Grant
11. Samplifys AutoFocus™ Beamforming Technology Awarded Electronic Designs Best of 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
Breaking Medicine News(10 mins):